Meta Pixel

News and Announcements

Horizon 3 Welcomes Dr.Tam Nguyen As Part of the Investment Committee

  • Published December 15, 2021 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

“Horizon 3 Biotech is excited to announce the addition of Dr.Tam Nguyen to our Investment Committee. Tam is a Non-Executive Director and Deputy Director of Research with over 15 years of board level experience across not for profit, healthcare and aged care sectors. He has over 22 years of working in the healthcare, health & medical research environment including tertiary teaching hospitals and medical research institutes. 

Register Interest

Tam holds senior executive role with strategic and operational responsibilities in research business development, research innovation and commercialisation and research strategy. He consults and speaks on a broad range of topics including industry collaboration (in the Medtech and Pharma Sectors), Digital Health, Digital Transformation and the application of AI in healthcare.  

Tam is well known in Australian clinical and commercial circles and his US network is also extensive. Tam works closely with Federal and State departments promoting Australia as the destination to conduct clinical trials. Tam is active with a number of professional bodies including AusBiotech, ARCS and the Society for Clinical Research Sites (SCRS). 

Tam is a graduate of the VC Catalyst Program from the Wade Institute (inaugural cohort) and was on short-term secondment with Brandon Capital Partners, one of the leading Seed and Venture Capital firms in Australia. 

Tam has a PhD in Biomechanics/Orthopaedic research and MBA in general management and strategy. He holds academic appointments with Melbourne Medical School and Monash Medical School and numerous fellowship appointments. 

We’re looking forward to welcoming Tam to the Investment team, and we are confident he will significantly strengthen Horizon 3’s ability to invest to improve lives globally.”

About the Company

Horizon 3 Biotech Fund is an unlisted unit trust allowing Wholesale Investors to invest in up to 10 companies that are advancing leading edge technologies in therapeutics, medical devices, diagnostics, and digital health.

We are an Australian-based venture capital fund investing in private and public life sciences companies both here in Australia and globally. We are led by a senior team of Life Sciences professionals with deep experience in VC biotech funds management, R&D innovation, clinical trials, and commercialisation in the Pharma and Life Sciences sector.

  • The Biotech sector is booming and we offer diversification into a high growth sector
  • We invest in later-stage public and private companies across drugs, devices, diagnostics and digital health with a 3-5 year investment time horizon.
  • We target a 20%+ IRR and make a positive contribution to society

Register Interest

Capital Insights
Dubai: The Unsung Bridge for Global Tech Investment and Market Access

In the bustling world of global tech and investment, Dubai is often seen through the lens of its impressive skyline and rapid development. However, beneath the gleaming facade lies a sophisticated ecosystem designed to be a crucial bridge for founders seeking capital and market access, and for investors looking to tap into burgeoning opportunities across […]

Capital Insights
Australia’s Trillion-Dollar Defence Tech Boom: A Call to Action for Founders

The global defence technology landscape is no longer a niche for the select few. For Australian founders, it represents a monumental, yet frequently underestimated, investment opportunity. Fuelled by escalating geopolitical tensions and a fundamental re-prioritisation of global spending, this sector is experiencing an unprecedented tailwind. According to Steve Baxter, Lead Investor at Beaten Zone Venture […]

Join over 45,000+ sophisticated investors

Join Now